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The enhancer of zeste homolog 2 (EZH2), one of the polycomb-group proteins, is the 
catalytic subunit of Polycomb-repressive complex 2 (PRC2) and induces the trimeth-
ylation of the histone H3 lysine 27 (H3K27me3) promoting epigenetic gene silencing. 
EZH2 contains a SET domain promoting the methyltransferase activity, while the three 
other protein components of PRC2, namely EED, SUZ12, and RpAp46/48, induce 
compaction of the chromatin permitting EZH2 enzymatic activity. Numerous studies 
highlight the role of this evolutionary conserved protein as a master regulator of differen-
tiation in humans involved in the repression of the homeotic gene and the inactivation of 
X-chromosome. Through its effects in the epigenetic regulation of critical genes, EZH2 
has been strongly linked to cell cycle progression, stem cell pluripotency, and cancer 
biology, being currently at the cutting edge of research. Most recently, EZH2 has been 
associated with hematopoietic stem cell proliferation and differentiation, thymopoiesis 
and lymphopoiesis. Several studies have evaluated the role of EZH2 in the regulation 
of T cell differentiation and plasticity as well as its implications in the development of 
autoimmune diseases and graft-versus-host disease (GVHD). The aim of this review 
is to summarize the current knowledge regarding the role of EZH2 in the regulation of 
the differentiation and function of T cells focusing on possible applications in various 
immune-mediated conditions, including autoimmune disorders and GVHD.
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inTRODUCTiOn
The enhancer of zeste homolog 2 (EZH2), one of the polycomb-group (PcG) proteins, is the catalytic 
subunit of Polycomb-repressive complex 2 (PRC2) and induces the trimethylation of the histone H3 
lysine 27 (H3K27me3) promoting epigenetic gene silencing (1, 2). EZH2 contains a SET domain 
promoting the methyltransferase activity, while the three other protein components of PRC2, namely 
EED, SUZ12, and RpAp46/48, induce compaction of the chromatin permitting the enzymatic activ-
ity of EZH2 (3). Numerous studies highlight the role of this evolutionary conserved protein as a 
master regulator of differentiation in humans involved in the repression of the homeotic (Hox) gene 
and the inactivation of X-chromosome (3–6).
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Through its implications in the epigenetic regulation of critical 
genes, EZH2 has been strongly linked to cell cycle progression (7), 
stem cell pluripotency (8, 9), and cancer biology being currently 
at the cutting edge of research. At the molecular level, maintaining 
proper levels of EZH2 is critical for the normal function of cells, 
while its aberrant expression has been implicated in the induction 
of cell proliferation and oncogenesis (10, 11). Interestingly, EZH2 
is aberrantly overexpressed in a variety of neoplasms compared 
to normal tissues (11, 12) and is currently the subject of intense 
research for the better understanding of cancer biology. Thus, 
EZH2 is currently evaluated as a new biomarker and a novel 
target for cancer therapy.
Most recently, EZH2 has been associated with hematopoietic 
stem cell proliferation and differentiation (13, 14), thymopoiesis 
(14), and lymphopoiesis (15). Numerous studies have evaluated 
the role of EZH2 in the regulation of T cell differentiation and 
plasticity as well as its implications in the development of autoim-
mune diseases and graft-versus-host disease (GVHD). Given the 
currently evolving development of EZH2 inhibitors for human 
malignancies, the introduction of these inhibitors as modulators 
of immune-mediated diseases and activation of the immune 
system in patients with cancers is a promising opportunity.
eZH2 AnD ReGULATiOn OF 
T CeLL DiFFeRenTiATiOn
T Cell Lineage Commitment
The exposure of naïve T helper (Th) cells to an antigen in the 
context of distinct extracellular microenvironment queues leads 
to differentiation into the effector lineages namely Th1, Th2, and 
Th17 expressing distinct cytokines genes (16, 17). It is known that 
Th1 lineage produces IFN-γ and is implicated in anti-microbial 
and anti-viral immunity, while Th2 cells produce IL-4 and are 
involved in immunity against parasites as well as in the pathogen-
esis of allergic reactions through the activation of B cells and the 
subsequent production of IgE antibodies inducing the activity of 
mast cells (18). Th17 cells produce mainly IL-17 and IL-22 and are 
critical for the protection against certain extracellular pathogens, 
such as Candida albicans and Staphylococcus aureus, but are also 
involved in the pathophysiology of autoimmune conditions, such 
as inflammatory bowel disease (19, 20). The differentiation of 
naïve Th cells is promoted by a variety of cytokines produced in 
the setting of localized or systemic inflammation and is associ-
ated with a pattern of expression of lineage-specific transcription 
factors. Particularly, IL-12 promotes the polarization toward Th1 
lineage associated with the induction of the T-bet transcriptional 
factor, while IL-4 potentiates the differentiation toward Th2 line-
age that is connected with induction of the GATA-3 transcription 
factor (21). For the differentiation of Th17 cells, TGF-beta, IL-6, 
and activation of STAT3 and RORγ transcription factors have 
indispensable roles (22).
The expression of the transcription factor forkhead box P3 
(FOXP3) defines a subset of CD4+ cells with inhibitory functions 
called T regulatory cells (Tregs). Natural Tregs differentiate in 
the thymus maintaining and expanding the FOXP3 expression 
with the involvement of IFN-γ, TGF-beta, and IL-2, while 
naïve FOXP3− cells can differentiate directly in the periphery to 
FOXP3+ de novo induced Tregs through the exposure to anti-
gens with the involvement mainly of TGF-beta. Natural Tregs 
expressing T-bet transcription factor are known to suppress the 
function and expansion of Th1 cells, while Treg expressing IRF4 
and Stat3 are critical for the inhibition of Th2 and Th17 cells, 
respectively (23). These conclusions highlight the importance 
of Tregs development and maintenance, which is controlled by 
numerous factors, including cytokines, transcription factors, and 
epigenetic regulators.
eZH2 and T Cell Differentiation
Recent studies highlight the role of EZH2 in the differentiation 
and plasticity of T cells and introduce a new critical player with 
possible therapeutic implications. Data presented in an early 
study by Raaphorst et  al. supported that the expression of the 
PcG proteins BMI-1 and EZH2 in mature peripheral T cells is 
mutually exclusive and associated with their proliferation status 
(24). Of note, particular patterns of EZH2 and BMI-1 expres-
sion characterize different stages of T cells differentiation in the 
thymus, suggesting a critical regulatory role of PcG proteins in 
lymphopoiesis through the stabilization of gene expression pat-
terns that will lead to a lineage choice (24).
Subsequent studies using EZH2-deficient T cells determined 
that EZH2 has a key role in the differentiation and plasticity of Th1 
and Th2 T cells and a mandatory role on the survival of T effector 
cells. Specifically, Zhang et al. evaluated the role of EZH2 expres-
sion in the differentiation of naïve CD4+ T cells and the survival of 
effector cells, using a model of transgenic EZH2fl/flCD4-Cre mice 
for T cell-specific EZH2 deletion (25). These studies revealed that 
the proportion of effector Th0, Th1, Th2, and Th17 but not iTreg 
cells in the EZH2fl/flCD4-Cre mice were decreased by day 6 after 
birth (25). Interestingly, the study showed that EZH2 deletion 
was associated with upregulation of IFN-γ and IL-10 under Th0 
conditions, enhanced induction of IFN-γ under Th1 conditions 
and increased expression of IL-10 under Th2 conditions (25). 
Similarly, Yang et al. showed that EZH2-deficient CD4+ T cells 
produce higher amounts of IFN-γ, IL-13, and IL-17 in Th1, Th2, 
and Th17 conditions, respectively, compared to control T cells, 
suggesting that EZH2 suppresses the expression of lineage 
signature cytokines (26). Together these studies indicate that 
EZH2 has an inhibitory role in the Th1 and Th2 differentiation 
(Figure 1A). These conclusions are consistent with the results of 
Tumes et al. who showed that EZH2-deficient Th cells produce 
more IFN-γ during stimulation in the presence of IL-12, which 
induces Th1 polarization and more IL-4, IL-5, and IL-13 during 
stimulation in the presence of IL-4, which induces Th2 polariza-
tion (27). Moreover, in the same study was found that EZH2-
deficient T cells express higher amounts of T-bet and Gata-3 (27), 
critical transcriptional factors for the Th1 and Th2 differentiation, 
respectively. Of note, Tumes et  al. showed that, compared to 
WT cells, Th1 polarized EZH2-deficient T cells express higher 
levels of IL-4, IL-5, and IL-13 when exposed to Th2 conditions 
and Th2 polarized EZH2-deficient T cells express higher levels 
of IFN-γ when exposed to Th1 conditions (27), suggesting that 
EZH2-deficient cells demonstrate increased plasticity. The inhibi-
tory role of EZH2 on Th2 differentiation was further confirmed 
by the finding that the transfer of oval-albumin (OVA)-specific 
FiGURe 1 | Summary of the functions of eZH2 in T cells, regulatory T cells, and cancer-mediated immune regulation. (A) EZH2 downregulates the 
expression of Th1/Th2 cytokines, such as IFN-γ and IL-4/IL-5, respectively, inhibiting the Th1/Th2 differentiation of naïve CD4+ T cells. EZH2 inhibits integrin-
dependent migration of T cells while promoting TCR-dependent actin polymerization. (B) In effector CD4+ T cells EZH2 inhibits the expression of apoptotic 
molecules, such as FAS, TNFR1, DR4, and Mlkl1, promoting their survival and sustaining the immune responses. (C) EZH2 downregulates the expression of IFN-γ 
and IL-4, while promoting the expression of Foxp3 and the activation of T regulatory cells. (D) In cancer cells, EZH2 inhibits the expression of Th1 chemokines, such 
as CXCL9 and CXCL10 thereby compromising the trafficking of CD8+ T cells, which mediate cytotoxic effects on cancer cells and promote anti-tumor function.
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EZH2-deficient Th2 cells in C57BL/6 mice was associated with 
the development of exaggerated allergic asthma characterized by 
increased eosinophilic inflammation and increased proportion 
of effector memory CD4+ T cells, which produced increased 
amounts of IL-4 and IL-5 compared to the transfer of WT Th2 
cells (27). These findings provided compelling evidence that 
EZH2 inhibits the differentiation and plasticity of naïve T cells. 
Based on these observations, it can be hypothesized that EZH2 
inhibitors might enhance immune responses. In this context, 
EZH2 inhibitors might promote IFN-γ-producing T cells and can 
be used in order to enhance anti-tumor immunity, while EZH2 
activating agents might serve as promising therapies for the sup-
pression of Th1- and Th2-dependent autoimmune diseases.
It should be noted that the results of the various groups 
regarding the role of EZH2 on Th1 and Th2 differentiation are 
not completely consistent (24–28). Specifically, whereas three 
investigator groups reported increased IFN-γ production from 
EZH2-deficient T cells cultured under Th1 polarizing conditions 
(25–27), Tong et  al. reported the opposite observation (28). 
This study found that downregulation of EZH2 decreases the 
production of IFN-γ under Th1 skewing conditions, which is 
not affected by neutralization of IL-4 and is not associated with 
differences in Gata-3 levels, suggesting that EZH2 promotes Th1 
differentiation in vitro independently of IL-4 and Gata-3 (28). The 
authors showed that loss of EZH2 promotes the development of 
a particular histone methylation signature for genes associated 
with Th1 differentiation such as Ifng, Tbx21, and Stat4 (28). 
These investigators also reported that EZH2 increases the stability 
of T-bet (28), suggesting a novel role of EZH2 as an inducer of Th1 
differentiation. Interestingly, enhancement of Th1 differentiation 
through EZH2 was associated with the development of T cell-
mediated aplastic anemia in transgenic mouse models, suggest-
ing that targeting EZH2 might be a possible therapeutic approach 
for the treatment of aplastic anemia (28). These results are in 
agreement with a study by Jacob et al. who found that chromatin 
binding of the EZH2 to cytokine promoters in CD4+ T cells is 
associated with induction of Th1 and Th2 cytokines, suggesting 
a positive role of EZH2 toward cytokine gene transcription in 
CD4+ T cells (29). However, it is possible that the reason for this 
discrepancy might be purely methodological. Specifically, it was 
observed that enhanced Th2 differentiation and increased pro-
duction of IL-4 by EZH2-deficient cells opposes Th1 polarization 
(25–27). Notably, the only study that observed decreased IFN-γ 
production – a hallmark of Th1 polarization – did not report the 
method of naïve T cell purification prior to in  vitro polarizing 
culture (28). Therefore, it is possible that different isolation meth-
ods and lower purification efficiency might have resulted in the 
diminished ability of naïve EZH2-deficient T cells to be polarized 
toward Th1 phenotype observed in this one study.
Although EZH2 is a known methyltransferase acting as 
epigenetic regulator, Su et al. highlighted a cytosolic function of 
this protein in mediating T cell receptor-induced actin polym-
erization and T cell differentiation (14). Subsequently, Gunawan 
et al. showed that EZH2 deficiency impairs integrin-dependent 
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migration of leukocytes affecting the progression of multiple 
sclerosis in a mouse autoimmune model further supporting a 
critical extranuclear function of EZH2 in the development of 
inflammation and autoimmune disease (30).
eZH2 and effector T Cells
Apart from the differentiation of naïve CD4+ T cells, the function 
of the immune system also depends on the survival of differenti-
ated immune cells. Zhang et al. found that EZH2 promotes the 
survival of differentiated effector T cells through inhibition of 
numerous apoptosis pathways, including Fas, TNFR1, DR4, and 
Mlk1 signaling (25) (Figure  1B). Consistent with this finding, 
Yang et al. showed that EZH2-deficient mice have decreased sur-
vival after intraperitoneal Toxoplasma gondii infection and this 
was associated with decreased numbers of IFN-γ producing CD4+ 
T cells in the peritoneal exudate (26). These observations suggest 
that EZH2 is critical for the generation of T effector cell responses 
in vivo, and the defects observed in EZH2-deficient mice were 
attributed to the decreased proliferation of EZH2 effector T cells. 
The conclusion that EZH2 is critical for the survival, proliferation, 
and activity of effector T cells was further supported by a study by 
He et al. who evaluated the role of EZH2 in the development of 
GVHD using a model of allogeneic bone marrow transplantation 
(31). Particularly, the authors showed that EZH2 is critical for the 
survival and proliferation of alloantigen-activated T cells and the 
development of GVHD in a major histocompatibility (MHC)-
mismatched B6 anti-BALB/C mouse model. In that system, 
IFN-γ producing alloreactive T cells are significantly diminished 
in the absence of EZH2 (31). Of note, the deletion of EZH2 did 
not affect the anti-leukemic effect of donor T cells in this mouse 
model (31). This observation suggested that inhibition of EZH2 
might be a reasonable approach to protect patients undergoing 
bone marrow transplantation from the development of GVHD 
without compromising the beneficial graft-versus-leukemia 
effect of allogeneic stem cell transplantation.
eZH2 and T Regulatory Cells
While the studies presented above supported a critical role of 
EZH2 on Th1 and Th2 differentiation of naïve CD4+ T cells with 
very tentative therapeutic implications, the deletion of EZH2 
has been associated with significant reduction of FOXP3 (25), 
suggesting that EZH2 may be critical for the activation of Tregs. 
FOXP3 co-localizes with EZH2 (32) and it has been shown that 
the absence of EZH2 is associated with impairment of iTreg dif-
ferentiation in vitro (25, 27). These studies also indicated a possi-
ble positive role of EZH2 in the regulation of Treg differentiation, 
activation, and suppressive function (Figure  1C). Yang et  al. 
evaluated the implication of EZH2 on Treg function and found 
that CD4-specific deletion of EZH2 in transgenic mice leads to 
significantly fewer naïve T cells and decreased FOXP3 expression 
in CD4 cells in the spleen and lymph nodes (26). Interestingly, 
the authors found that the addition of antibodies against IFN-γ 
and IL-4 reverses the impaired FOXP3 expression in EZH2-
deficient T cells (26). This observation is consistent with the data 
of Zhang et al. showing that the FOXP3 reduction due to EZH2 
deficiency is reversed in the presence of IFN-γ blocking antibody 
(25). These findings imply that the downregulation of FOXP3 in 
EZH2-deficient cells is likely mediated by aberrant production 
of cytokines, such as IFN-γ and IL-4. To expand these findings 
and understand their biological implications in vivo, Yang et al. 
studied the functional implications of EZH2 deficiency on the 
properties of Tregs and determined that EZH2-deficient Tregs 
failed to protect from the development of autoimmunity in a 
model of naïve T cell-mediated colitis in vivo (26).
Further highlighting the critical role of EZH2 in the activation 
of Tregs, DuPage et al. showed that, at the transcription level, EZH2 
is the most abundant chromatin modifier induced by CD28 acti-
vation in naïve CD4+ T cells (33). This is consistent with previous 
reports supporting that the epigenetic state of Tregs is regulated 
by pathways related to the T cell receptor-mediated stimulation 
(34, 35). More importantly, Treg-specific EZH2 deletion renders 
Tregs phenotypically normal and functional in vitro but unable to 
properly maintain immune homeostasis in vivo, as supported by 
the fact that Treg.EZH2Δ/Δ mice presented numerous signs of 
autoimmunity, including weight and hairy loss and scaly tails (33). 
The authors showed that EZH2 is responsible for the maintenance 
of the repressive gene program after Treg activation, which is criti-
cal for the recruitment and function of Tregs at the site of inflam-
mation (33). These results support an important role of EZH2 in 
the activity of Tregs, which may have significant implications not 
only in the context of autoimmune diseases and cancer.
eZH2 and Regulation of Anti-Tumor 
immunity
Despite the extensive research evaluating the role of EZH2 as 
a promoter of cancer progression through the induction of cell 
cycle and inhibition of cancer cell differentiation, the effects of 
EZH2 expression on the tumor immunity have not been fully 
appreciated. According to a recent publication by Peng et  al., 
epigenetic alterations of cancer cells by inhibition of EZH2 
and DNA methyltransferase 1 (DNMT1) in a mouse model 
of ovarian cancer resulted in increased expression of the Th1-
type chemokines CXCL9 and CXCL10 in cancer cells leading 
to increased trafficking of effector T cells to the tumor site and 
decreased tumor volume (36). Conversely, increased expression 
of EZH2 and DNMT1 in ovarian tumors was associated with 
decreased infiltration of CD8+ T cells and worse prognosis (36) 
(Figure  1D). Furthermore, treatment of ovarian tumors with 
EZH2 and DNMT1 inhibitors increased the efficacy of tumor-
associated antigen-specific CD8+ T cells in response to PD-L1 
inhibition. A similar effect of EZH2 was observed in colorectal 
cancer, where targeting EZH2 in cancer cells augments the 
expression of CXCL9 and CXCL10 chemokines affecting the 
infiltration of the tumor by effector T cells (37). These results 
support the conclusion that the tumorigenic effects of histone 
modifications and DNA methylation in cancer cells may be medi-
ated by alteration of immunity in the tumor microenvironment. 
This conclusion may lead to the introduction of novel therapeutic 
strategies to improve the efficacy of immunotherapy.
COnCLUSiOn
Enhancer of zeste homolog 2 is a methyltransferase, member of 
the PRC2 complex acting as epigenetic regulator with critical 
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implications in maintaining the gene signature particularly associ-
ated with cell cycle progression, proliferation, and differentiation. 
Recent studies suggest that EZH2 has significant implications in 
carcinogenesis and is a novel target in cancer therapeutics. While 
EZH2 inhibitors are currently under intense investigation, the 
implications of EZH2 in the regulation of T cell differentiation 
and activity are only now starting to be unraveled. Such effects of 
EZH2 are of particular interest because targeting T cells-specific 
EZH2 functions may have significant implications for the con-
trol of autoimmunity, alloreactivity, and anti-tumor immunity. 
Strikingly, EZH2 appears to function as a crosstalk regulator 
between cancer and T cells and modulation of EZH2 expression 
in cancer cells alters their ability to produce Th1-type chemokines 
and to attract CD8+ T effector cells, which mediate anti-tumor 
function especially in the context of checkpoint blockade immu-
notherapy. Importantly, EZH2 has activity not only on T effector 
cells but also on Tregs, rendering the therapeutic targeting of 
EZH2 a uniquely complex challenge. Further studies will be 
required to clarify the effects of EZH2 on the differentiation, sur-
vival, and function of Th, T effector, and Tregs in order to create 
novel therapeutic strategies in the area of autoimmune diseases, 
allogeneic transplantation, and cancer.
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